MENLO PARK, Calif., Nov. 18 /PRNewswire/ -- Apieron, Inc. has asked the court presiding over its patent suit against Aerocrine, Inc. to allow it to raise additional grounds for invalidating Aerocrine's broadest patent relating to exhaled nitric oxide, U.S. Patent No.

MENLO PARK, Calif., July 22 /PRNewswire/ -- Apieron, Inc. said today that CareFirst BlueCross BlueShield has adopted a positive coverage policy for the measurement of exhaled nitric oxide (eNO).

MENLO PARK, Calif., July 16 /PRNewswire/ -- Today, Apieron, Inc. reported that it filed a patent infringement complaint against Aerocine AB, Solna, Sweden, Aerocrine AG, Bad Homburg, Germany and Mr. Mangus Pelles, Usingen, Germany in the Regional Court of Mannheim, Germany.

Panel also addresses limitations of current randomized trials MENLO PARK, Calif., June 2 /PRNewswire/ -- Apieron, Inc. highlighted recent clinical panel presentations underscoring the positive impact of measuring exhaled nitric oxide (eNO) for treating asthma in adults and children.

MENLO PARK, Calif., June 1 /PRNewswire/ -- In its Series D round of fundraising, Apieron Inc. said that it closed on commitments from all of its previous venture investors.